Harold Keer joined Astex Pharmaceuticals, Inc. in February 2013, and was appointed Chief Medical Officer in November 2020. He possesses more than 20 years of drug development experience in industry and academia. From 2008 to 2013, Dr. Keer served as Vice President, Clinical Development at Five Prime Therapeutics where he led clinical development for programs in oncology and immunology. From 2002 to 2008 he was at Exelixis where he held multiple roles with increasing responsibility including Vice President, Clinical Development. At Exelixis he was responsible for oversight of multiple clinical development clinical programs including for Cometriq®, now approved for thyroid cancer. Dr. Keer received his MD and PhD degrees from Northwestern University Medical School, completed training in Internal Medicine at Harvard-affiliate, Beth Israel Hospital, and completed sub-specialty training in Medical Oncology at Stanford University School of Medicine where he was awarded a Clinical Associate Physician grant to perform clinical and translational research. He has published many scientific papers and abstracts, including in the New England Journal of Medicine. Dr. Keer is Adjunct Clinical Faculty at Stanford.

Ulrike Köhl is a full Professor for Immune Oncology at the University of Leipzig, Germany and the director of the Fraunhofer Institute for Cell Therapy and Immunology since 2017 as well as director of the Institute of Cellular Therapeutics at Hannover Medical School since 2012, respectively. She holds a degree in in biology supplemented by a medicine study. She worked at the MD Anderson Cancer Centre in Houston, USA and at the University Hospital, Frankfurt, Germany. She is an international leading expert in the development and manufacturing of cell and gene therapies in cancer and regenerative medicine and collaborates with both international industry and academic partners. Main focus includes chimeric antigen receptor (CAR) expressing T and especially NK effector cells for clinical trials. Currently, U. Köhl is heading “SaxoCell”, a cluster of excellence for cell and gene therapy, funded by the Germany federal government as well as the IMI EU consortium “ImSAVAR”. She is a member of numerous national and international societies, committee member of scientific advisory boards and is serving as a reviewer for authorities, respectively.

Dr. Nicolaus Kröger is Professor of Medicine and Medical Director of the Department of Stem Cell Transplantation at the University Medical Center Hamburg-Eppendorf, Germany. Prof. Kröger is board certified in Hematology-Oncology and Internal Medicine. From 2018 to 2022 he was President of the European Society of Blood and Marrow Transplantation (EBMT) and from 2012 to 2018 Chairman of the Chronic Malignancy Working Party of EBMT and from 2014 to 2018 Scientific Council Chair of EBMT He served also as chairman of the German Stem Cell Working Group (DAG-KBT) from 2014-2020 and is member of several editorial boards such as Blood, Haematologica, Bone Marrow Transplantation and Biology of Blood and Marrow Transplantation. He is Co-Editor of the EBMT Handbook and the EBMT/EHA CAR-T Cell Handbook and also member of numerous Scientific Committees such as ASH, EHA, and ESH. He has received several awards for his work to date including the prestigious EBMT van Bekkum Award in 2015. In 2020 he was awarded as Doctor Honoris Causa from the University Belgrade. Prof. Kröger has published extensively in his area of expertise and has contributed to more than 800 publications in peer-reviewed journals such as NEJM, Lancet, JCO, JNCI, PNAS, Blood and Leukemia.

Anne Sophie Kubasch is a fellow and clinician scientist at the Department of Hematology, Cellular Therapy and Hemostaseology at University Hospital Leipzig. She is the co-project lead of “KAIT”, an AI-driven diagnostic and therapeutic decision support tool in hematology, which is currently being developed as a collaborative project between the “Innovation Center for Computer Assisted Surgery Leipzig” (ICCAS) and the University Hospital Leipzig. In 2020, she received a research fellowship of the “José Carreras Leukämie Stiftung e.V.” for her project on the identification of new personalized treatment approaches to improve patient stratification and therapeutic outcome in myelodysplastic syndromes (MDS). Her clinical expertise focuses on patients with MDS and AML. Within the "German MDS Study Group" (D-MDS) and the "European Myelodysplastic Syndromes Cooperative Group" (EMSCO) she is involved as PI and Co-PI in various translational clinical studies with the aim to identify new precise, personalized treatment options for patients with MDS. https://de.linkedin.com/in/dr-anne-sophie-kubasch-02b943ab https://twitter.com/askubasch?lang=de

I am Dr. Sandra Kurtin. I received my BSN, MS in oncology nursing, post-graduate certification in geriatric and adult practice, and most recently, my PhD in nursing at the University of Arizona. I hold appointments as an Assistant Professor of Clinical Medicine and Adjunct Clinical Assistant Professor of Nursing at The University of Arizona. I am currently The Director of Advanced Practice and a Hematology/Oncology Nurse Practitioner at The University of Arizona Cancer Center where I have practiced for 38 years, 30 of those in Advanced Practice. I am honored to be an inaugural Fellow of Advanced Practice in Oncology (FAPO). I am a founding board member and the immediate past-president of the Advanced Practitioner Society for Hematology and Oncology (APSHO), as well as a member of American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), American Academy of Nurse Practitioners (AANP), and Oncology Nursing Society (ONS). In addition, she is a member of the executive committee, board of directors and co-chair of the Nursing Leadership Board for the MDS Foundation. I also serve on the Hematology Board for the American Board of Internal Medicine. I have been an associate editor for The Journal of the Advanced Practitioner in Oncology since its inception. I am also an editorial board member for JCO Clinical Cancer Informatics, ASH News, The Clinical Journal of Oncology Nursing, and the ASCO People Living with Cancer website. I have presented numerous regional, national, and international lectures on oncology related topics and has published numerous articles in peer-reviewed journals including the New England Journal of Medicine, Cancer Nursing, Clinical Leukemia, Blood, Leukemia Research, The Journal of the Advanced Practitioner in Oncology, and The Clinical Journal of Oncology Nursing. My research focuses on heath technology engagement and communicative health literacy aimed at improving health self-management among older adult cancer survivors and their caregivers, as well as practice transformation to achieve best practice.